Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Siglecs in innate immunity.

Paul R Crocker1

  • 1Division of Cell Biology and Immunology, The Wellcome Trust Biocentre, University of Dundee, Dow Street, Dundee DD1 5EH, UK. p.r.crocker@dundee.ac.uk

Current Opinion in Pharmacology
|June 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sialoadhesin (CD169/Siglec-1) is an extended molecule that escapes inhibitory cis-interactions and synergizes with other macrophage receptors to promote phagocytosis.

Glycoconjugate journal·2023
Same author

Activation of regulatory T cells triggers specific changes in glycosylation associated with Siglec-1-dependent inflammatory responses.

Wellcome open research·2022
Same author

Quantitative Proteomics of Polarised Macrophages Derived from Induced Pluripotent Stem Cells.

Biomedicines·2022
Same author

Siglec-7 Mediates Immunomodulation by Colorectal Cancer-Associated <i>Fusobacterium nucleatum</i> ssp. <i>animalis</i>.

Frontiers in immunology·2021
Same author

Siglec and anti-Siglec therapies.

Current opinion in chemical biology·2021
Same author

Dissemination of <i>Mycobacterium tuberculosis</i> is associated to a <i>SIGLEC1</i> null variant that limits antigen exchange via trafficking extracellular vesicles.

Journal of extracellular vesicles·2021
Same journal

Targeting the ischemic cascade: Review on approved and investigational stroke therapies.

Current opinion in pharmacology·2026
Same journal

Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives.

Current opinion in pharmacology·2026
Same journal

Chrono-immunotherapy in precision oncology: Circadian control of the tumor microenvironment and time-of-day optimization of immune checkpoint blockade.

Current opinion in pharmacology·2026
Same journal

Methotrexate: Integrating molecular pharmacology, systems toxicology, and precision rescue strategies.

Current opinion in pharmacology·2026
Same journal

Acupuncture and non-invasive neuromodulation-induced neuro-endocrine-immune changes associated with the amelioration of depression-like behaviors: A systematic review of animal studies.

Current opinion in pharmacology·2026
Same journal

Alopecia areata: Mechanisms, targeted therapies, and translational challenges.

Current opinion in pharmacology·2026
See all related articles

Sialic acid-binding Ig-like lectins (Siglecs) are key immune system receptors. They regulate cell signaling, adhesion, and can be entry points for pathogens, offering therapeutic targets.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Siglecs are sialic acid-binding Ig-like lectins involved in cell signaling and adhesion.
  • CD33-related Siglecs are evolving within the innate immune system, influencing apoptosis and inhibition.
  • CD22 is a B cell-specific Siglec regulating B cell function via sialic acid-dependent and -independent pathways.

Purpose of the Study:

  • To explore the multifaceted roles of Siglecs in the immune system.
  • To highlight the significance of CD33-related Siglecs in innate immunity.
  • To discuss CD22's function in B cell regulation.

Main Methods:

  • Review of existing literature on Siglec structure and function.
  • Analysis of Siglec expression patterns in immune cells.

Related Experiment Videos

  • Investigation of Siglec-mediated signaling pathways.

    • Main Results:

    • Siglecs act as crucial regulators of immune cell interactions and responses.
    • CD33-related Siglecs possess potent immunomodulatory capabilities.
    • Siglecs serve as pathogen entry points and potential therapeutic targets.

    Conclusions:

    • Siglecs are versatile receptors with critical roles in innate and adaptive immunity.
    • Targeting Siglecs offers promising therapeutic strategies for immune-related diseases.
    • Further research into Siglec biology will advance our understanding of immune regulation.